Related Experiment Video
Updated: Jul 9, 2026
07:09
Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States
Published on: April 1, 2015
Increased platelet aggregation in early diabetus mellitus
Annals of Internal Medicine
|June 1, 1975
Summary
Platelet aggregation is increased early in diabetes mellitus, potentially contributing to vascular disease. Therapeutic agents like acetylsalicylic acid may reverse this effect, warranting further study.
Area of Science:
- Endocrinology
- Hematology
- Vascular Biology
Background:
- Diabetes mellitus is associated with an increased risk of vascular disease.
- Platelet aggregation plays a critical role in hemostasis and thrombosis.
- Understanding platelet function in diabetes is crucial for preventing vascular complications.
Purpose of the Study:
- To investigate platelet aggregation patterns in individuals with varying degrees of glucose intolerance, from prediabetes to frank diabetes.
- To determine the relationship between platelet sensitivity to aggregating agents and the severity of diabetes.
- To explore the potential of therapeutic interventions in modulating platelet aggregation in diabetic subjects.
Main Methods:
- Comparative analysis of platelet aggregation in normal, prediabetic, latent diabetic, and frankly diabetic subjects.
- Assessment of platelet response to adenosine 5'-diphosphate, epinephrine, and collagen.
- Evaluation of the effects of acetylsalicylic acid, intravenous tolbutamide, and oral glucose on second-phase platelet aggregation.
Main Results:
- Significantly increased platelet aggregation was observed in latent and frankly diabetic subjects compared to normal controls.
- Platelet sensitivity to aggregating agents was dose-dependent and most pronounced in frank diabetics.
- Prediabetic individuals showed a trend towards increased platelet aggregation.
- Second-phase platelet aggregation was effectively reversed by acetylsalicylic acid, tolbutamide, and glucose administration.
Conclusions:
- Platelet hyperaggregability may be an early indicator of diabetes mellitus.
- Increased platelet aggregation is likely involved in the pathogenesis of diabetic microangiopathy.
- Further research into therapeutic agents like acetylsalicylic acid is warranted to assess their impact on diabetic vascular disease progression.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:22Formation of the Platelet Plug
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
01:25Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...
01:29Hyperglycemia
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
01:27Diabetic Retinopathy
DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...